- Report
- June 2025
- 192 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 196 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 196 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 94 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 262 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 375 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 340 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 288 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 72 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- May 2025
- 300 Pages
Global
From €4433EUR$4,949USD£3,779GBP
- Report
- August 2024
- 150 Pages
Global
From €2498EUR$2,789USD£2,129GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1344EUR$1,500USD£1,145GBP
- Report
- June 2024
- 120 Pages
Global
From €3583EUR$4,000USD£3,054GBP
- Report
- February 2025
- 221 Pages
Global
From €2239EUR$2,500USD£1,909GBP
- Report
- August 2024
- 178 Pages
Global
From €2239EUR$2,500USD£1,909GBP
- Drug Pipelines
- April 2025
- 240 Pages
Global
From €2687EUR$3,000USD£2,291GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €1120EUR$1,250USD£954GBP
- Report
- May 2025
- 183 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- April 2025
- 184 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- February 2025
- 184 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP

The Sodium Dependent Glucose Co Transporter 2 (SGLT2) market is a subset of the Endocrine and Metabolic Disorders Drugs market. SGLT2 inhibitors are a class of drugs used to treat type 2 diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin effectively. These drugs work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to reduce blood glucose levels and improve glycemic control.
The SGLT2 market is highly competitive, with several major pharmaceutical companies offering products. These include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Merck, Novo Nordisk, and Sanofi. Each company offers a range of products, including both branded and generic versions. Show Less Read more